Our study demonstrates that up-regulated NID2 plays an important role in promoting the invasion and migration of gastric cancer cells and has a potential of being a novel biomarker for diagnosis treatment and prognosis of gastric cancer in the future.
the serum NID2 levels show significant elevation in the ESCC patients and those with relatively high serum NID2 levels ( 32.6 mu mu g/L) are significantly associated with poor survival outcome compared with those with very low serum NID2 levels (< < 20.0 mu mu g/L).
Addition of a TWIST1/NID2-based DNA methylation assay adds diagnostic value to urine cytology and the model is sensitive to the classification of equivocal cytology.
Promoter methylation of NID2 was significantly higher in nasopharyngeal carcinoma and esophageal squamous cell carcinoma cells. NID2 suppresses the EGFR/Akt and integrin/FAK/PLCgamma metastasis-related pathways.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.